Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance …
LP Vegas, L Penso, E Sbidian, P Claudepierre - RMD open, 2023 - rmdopen.bmj.com
Background Sex differences in phenotype presentation, disease trajectory and treatment
response in psoriatic arthritis (PsA) have been reported. Nevertheless, whether classes of …
response in psoriatic arthritis (PsA) have been reported. Nevertheless, whether classes of …
Issues with pregnancy in systemic lupus
V Le Guern, G Guettrot-Imbert, A Dupré, S Perol… - Joint Bone Spine, 2024 - Elsevier
Systemic lupus erythematosus is a disease that affects a large number of young women of
childbearing age. Today, pregnancy is considered safe in almost all women with lupus …
childbearing age. Today, pregnancy is considered safe in almost all women with lupus …
Domestic Animal Models of Central Nervous System Tumors: Focus on Meningiomas
Intracranial primary tumors (IPTs) are aggressive forms of malignancies that cause high
mortality in both humans and domestic animals. Meningiomas are frequent adult IPTs in …
mortality in both humans and domestic animals. Meningiomas are frequent adult IPTs in …
Radiological evolution of progestogen‐induced meningioma: A monocentric retrospective study
T Ahmed‐Khalifa, R Gillet, M Blonski… - Fundamental & …, 2023 - Wiley Online Library
Cyproterone acetate (CPA) is known to induce meningioma, and recently, nomegestrol
acetate (NMA) and chlormadinone acetate (CMA) were also involved. Progestagen‐induced …
acetate (NMA) and chlormadinone acetate (CMA) were also involved. Progestagen‐induced …
Progestins and meningiomas
G Plu-Bureau - Annales d'Endocrinologie, 2023 - Elsevier
The annual incidence (standardized according to age and gender) of all meningiomas is
between 1 and 8/100,000 per year according to the main registers available worldwide (1) …
between 1 and 8/100,000 per year according to the main registers available worldwide (1) …
Pharmacoepidemiology and public decision
Pharmacoepidemiology and public decision Pharmacoepidemiology and public decision
Therapie. 2023 Sep-Oct;78(5):549-551. doi: 10.1016/j.therap.2023.01.001. Epub 2023 Jan …
Therapie. 2023 Sep-Oct;78(5):549-551. doi: 10.1016/j.therap.2023.01.001. Epub 2023 Jan …
Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review
AG Leone, S Bonadonna, C Cassani… - BMJ …, 2024 - bmjoncology.bmj.com
Transgender and gender-diverse (TGD) individuals face an elevated risk of cancer in
comparison with the general population. This increased risk is primarily attributed to an …
comparison with the general population. This increased risk is primarily attributed to an …
Utilisation de progestatifs et risque de méningiome intracrânien: une étude cas-témoins à partir des données du Système national des données de santé (SNDS)
N Roland, A Neumann, L Hoisnard, L Duranteau… - Journal of Epidemiology …, 2024 - Elsevier
Introduction L'utilisation prolongée à haute dose de trois progestatifs (acétate de
cyprotérone, de chlormadinone et de nomégestrol) augmente fortement le risque de …
cyprotérone, de chlormadinone et de nomégestrol) augmente fortement le risque de …
[PDF][PDF] The Role of Hormone Receptor Expression and Hormonal Therapy (Estrogen and Progesterone) in the Management and Prognosis of Meningiomas in …
BL Awosusi, J Ayyub, KN Dabhi, NV Gohil… - Journal for International …, 2023 - jimgs.com
Meningioma is the primary central nervous system tumour with the highest recorded
prevalence. Research on meningiomas has shown an association with hormone receptor …
prevalence. Research on meningiomas has shown an association with hormone receptor …
[PDF][PDF] Évaluation de l'impact des mesures de réduction du risque de méningiomes intracrâniens lié à l'utilisation de fortes doses d'acétate de cyprotérone en France
A Neumann, P Dayani, L Duranteau, I Yoldjian… - 2022 - epi-phare.fr
Les déclarations d'intérêt des auteurs, tous salariés de la Caisse nationale de l'assurance
maladie (Cnam), de l'Agence nationale de sécurité du médicament et des produits de santé …
maladie (Cnam), de l'Agence nationale de sécurité du médicament et des produits de santé …